MARKET

CCXI

CCXI

Chemocentryx
NASDAQ
51.66
-0.02
-0.04%
After Hours: 51.66 0 0.00% 19:20 09/29 EDT
OPEN
51.68
PREV CLOSE
51.68
HIGH
51.74
LOW
51.60
VOLUME
1.84M
TURNOVER
0
52 WEEK HIGH
51.85
52 WEEK LOW
14.95
MARKET CAP
3.72B
P/E (TTM)
-27.3826
1D
5D
1M
3M
1Y
5Y
ChemoCentryx's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.
Benzinga · 09/01 14:20
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orall...
GlobeNewswire · 08/24 12:30
Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 08/16 16:00
ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks · 08/16 13:55
Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's notes; stable outlook
Rating Action: Moody's assigns Baa1 rating to Amgen's notes; stable outlookGlobal Credit Research - 15 Aug 2022New York, August 15, 2022 -- Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured notes offering of Amgen Inc...
Moody's · 08/15 14:35
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Zacks · 08/12 10:05
--Stifel Cuts ChemoCentryx to Hold From Buy, Price Target to $52 From $86
--Stifel Cuts ChemoCentryx to Hold From Buy, Price Target to $52 From $86
MT Newswires · 08/10 07:58
ChemoCentryx: Q2 Earnings Insights
  ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 08/09 20:56
More
About CCXI
ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The Company's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. It markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCXI stock methods without spending real money on the virtual paper trading platform.